4A). All treatment arms significantly inhibited xenograft growth, particularly lapatinib/trastuzumab, LJM716/trastuzumab and the 3-drug combination. Mice treated with any of these three combinations exhibited a close to total response with tumors measuring 25% growth inhibition (GI) relative to control, in 6/18 (33%) cell lines as measured by the cell content of ATP (CellTiterGlo assay). Treatment […]